The complement component C3a fragment is a potential biomarker for hepatitis C virus-related hepatocellular carcinoma

[1]  K. Koike.  Steatosis, liver injury, and hepatocarcinogenesis in hepatitis C viral infection , 2009, Journal of Gastroenterology.

[2]  H. Otu,et al.  Serum Proteomics and Biomarkers in Hepatocellular Carcinoma and Chronic Liver Disease , 2008, Clinical Cancer Research.

[3]  C. Kalogeropoulou,et al.  Oval cell proliferation in cirrhosis in rats. An experimental study , 2007, Hepatology research : the official journal of the Japan Society of Hepatology.

[4]  K. Hayashi,et al.  Early diagnostic potential for hepatocellular carcinoma using the SELDI ProteinChip system , 2007, Hepatology.

[5]  N. Tanaka,et al.  Efficacy and safety of 6-month iron reduction therapy in patients with hepatitis C virus-related cirrhosis: a pilot study , 2007, Journal of Gastroenterology.

[6]  J. M. Roman,et al.  Increased serum levels of complement C3a anaphylatoxin indicate the presence of colorectal tumors. , 2006, Gastroenterology.

[7]  Alain Van Dorsselaer,et al.  Discovery and identification of potential biomarkers in a prospective study of chronic lymphoid malignancies using SELDI-TOF-MS. , 2006, Journal of proteome research.

[8]  D. Ward,et al.  Identification of serum biomarkers for colon cancer by proteomic analysis , 2006, British Journal of Cancer.

[9]  R. Hickey,et al.  Serum proteome profiles identifies parathyroid hormone physiologic response , 2006, Proteomics.

[10]  Ding‐Shinn Chen,et al.  Identification of complement C3a as a candidate biomarker in human chronic hepatitis C and HCV‐related hepatocellular carcinoma using a proteomics approach , 2006, Proteomics.

[11]  R. Gish,et al.  Hepatocellular carcinoma: overcoming challenges in disease management. , 2006, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[12]  Xiao-Ying Meng,et al.  Independent validation of candidate breast cancer serum biomarkers identified by mass spectrometry. , 2005, Clinical chemistry.

[13]  Y. Hoshida,et al.  Proteomic analysis of sera from hepatocellular carcinoma patients after radiofrequency ablation treatment , 2005, Proteomics.

[14]  Hung-Sheng Chen,et al.  Usefulness of serum des-γ-carboxy prothrombin in detection of hepatocellular carcinoma , 2005 .

[15]  O John Semmes,et al.  SELDI‐TOF MS profiling of serum for detection of the progression of chronic hepatitis C to hepatocellular carcinoma , 2005, Hepatology.

[16]  S. Meri,et al.  Ascitic complement system in ovarian cancer , 2005, British Journal of Cancer.

[17]  Pierre Bedossa,et al.  Identification of a new marker of hepatocellular carcinoma by serum protein profiling of patients with chronic liver diseases , 2005, Hepatology.

[18]  John D Lambris,et al.  C3a and C3b Activation Products of the Third Component of Complement (C3) Are Critical for Normal Liver Recovery after Toxic Injury1 , 2004, The Journal of Immunology.

[19]  G. Jung,et al.  Comparison of proteome between hepatitis B virus- and hepatitis C virus-associated hepatocellular carcinoma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[20]  Y. Kato,et al.  Rapid discovery and identification of a tissue-specific tumor biomarker from 39 human cancer cell lines using the SELDI ProteinChip platform. , 2003, Biochemical and biophysical research communications.

[21]  J. Marrero,et al.  Des‐gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients , 2003, Hepatology.

[22]  R. Dwek,et al.  A strategy for the comparative analysis of serum proteomes for the discovery of biomarkers for hepatocellular carcinoma , 2003, Proteomics.

[23]  K. Taketa,et al.  Evaluation of tumor markers for the detection of hepatocellular carcinoma in Yangon General Hospital, Myanmar. , 2002, Acta medica Okayama.

[24]  P. Schellhammer,et al.  Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. , 2002, Cancer research.

[25]  K. Taketa,et al.  Clinical Evaluation of Lentil Lectin-Reactive Alpha-Fetoprotein-L3 in Histology-Proven Hepatocellular Carcinoma , 2001, The International journal of biological markers.

[26]  John D Lambris,et al.  Structure and biology of complement protein C3, a connecting link between innate and acquired immunity , 2001, Immunological reviews.

[27]  M. Honda,et al.  Differential gene expression between chronic hepatitis B and C hepatic lesion. , 2001, Gastroenterology.

[28]  Y. Ueno,et al.  Simultaneous measurements of serum α-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma , 2000, American Journal of Gastroenterology.

[29]  Masakazu Yamamoto,et al.  Serum levels of des‐γ‐carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma , 2000, Cancer.

[30]  Z. Fishelson,et al.  Complement resistance of tumor cells: basal and induced mechanisms. , 1999, Molecular immunology.

[31]  H. El‐Serag,et al.  Rising incidence of hepatocellular carcinoma in the United States. , 1999, The New England journal of medicine.

[32]  H. Asakura,et al.  The usefulness of determining des‐γ‐carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma , 1998, Cancer.

[33]  A. Shevchenko,et al.  Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. , 1996, Analytical chemistry.

[34]  C. Legnani,et al.  The role of tumor markers in the diagnosis of hepatocellular carcinoma, with special reference to the des-gamma-carboxy prothrombin. , 1995, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[35]  Kenzo Kobayashi,et al.  Prospective study of α‐fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma , 1994 .

[36]  Kenzo Kobayashi,et al.  Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis , 1990, Hepatology.

[37]  A. Lok,et al.  α‐fetoprotein monitoring in chinese patients with chronic hepatitis B virus infection: Role in the early detection of hepatocellular carcinoma , 1989, Hepatology.

[38]  P. Garred,et al.  Effect of time, temperature and anticoagulants on in vitro complement activation: consequences for collection and preservation of samples to be examined for complement activation. , 1988, Clinical and experimental immunology.

[39]  H. Verhaegen,et al.  Increase of serum complement levels in cancer patients with progressing tumors , 1976, Cancer.

[40]  K. Hayashi,et al.  Spontaneous elimination of hepatitis C virus RNA in individuals with persistent infection in a hyperendemic area of Japan. , 2006, Hepatology research : the official journal of the Japan Society of Hepatology.

[41]  Kuan‐Yang Chen,et al.  Usefulness of serum des-gamma-carboxy prothrombin in detection of hepatocellular carcinoma. , 2005, World journal of gastroenterology.

[42]  Y. Ueno,et al.  Simultaneous measurements of serum alpha-fetoprotein and protein induced by vitamin K absence for detecting hepatocellular carcinoma. South Tohoku District Study Group. , 2000, The American journal of gastroenterology.

[43]  S. Edwards,et al.  Vitronectin induces migration of activated T lymphocytes , 2000 .

[44]  A. Tamori,et al.  Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. , 1994, Hepatology.

[45]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.